Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026
PRNewswire (Mon, 9-Mar 9:00 AM ET)
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results
PRNewswire (Thu, 5-Mar 7:00 AM ET)
Evogene Releases CEO Letter to Shareholders
PRNewswire (Wed, 25-Feb 8:00 AM ET)
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release
PRNewswire (Thu, 19-Feb 8:00 AM ET)
PRNewswire (Tue, 17-Feb 8:00 AM ET)
PRNewswire (Wed, 11-Feb 8:00 AM ET)
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds
PRNewswire (Tue, 10-Feb 1:20 PM ET)
Evogene Bolsters Scientific Advisory Board with World-Class Leaders to Drive ChemPass AI™ Innovation
Market Chameleon (Tue, 10-Feb 5:39 AM ET)
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI
PRNewswire (Tue, 10-Feb 8:01 AM ET)
Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
PRNewswire (Mon, 9-Feb 8:00 AM ET)
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
Evogene Ltd. - trades on the NASDAQ stock market under the symbol EVGN.
As of March 24, 2026, EVGN stock price declined to $0.88 with 142,410 million shares trading.
EVGN has a beta of 0.72, meaning it tends to be less sensitive to market movements. EVGN has a correlation of 0.04 to the broad based SPY ETF.
EVGN has a market cap of $7.69 million. This is considered a Sub-Micro Cap stock.
Last quarter Evogene Ltd. - reported $314,000 in Revenue and -$.61 earnings per share. This beat revenue expectation by $39,000 and missed earnings estimates by -$.35.
In the last 3 years, EVGN traded as high as $14.40 and as low as $.73.
EVGN has underperformed the market in the last year with a return of -36.1%, while the SPY ETF gained +17.1%. In the last 3 month period, EVGN fell short of the market, returning -15.6%, while SPY returned -4.8%. However, in the most recent 2 weeks EVGN has outperformed the stock market by returning +15.3%, while SPY returned -3.4%.
EVGN support price is $.88 and resistance is $.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVGN shares will trade within this expected range on the day.
